ciglitazone has been researched along with MS (Multiple Sclerosis) in 2 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schmidt, S | 1 |
| Moric, E | 1 |
| Schmidt, M | 1 |
| Sastre, M | 1 |
| Feinstein, DL | 1 |
| Heneka, MT | 1 |
| Niino, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability[NCT00242177] | Phase 1 | 30 participants | Interventional | 2003-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ciglitazone and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.
Topics: Animals; Anti-Inflammatory Agents; Encephalomyelitis, Autoimmune, Experimental; Humans; Multiple Scl | 2007 |
1 other study available for ciglitazone and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Anti-Inflammatory Agents; Case-Control Studies; Cell Divi | 2004 |